SEC Form 4 · accession 0000919574-15-008551
Celator Pharmaceuticals Inc · CPXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott D Morenstein
Director
Period of report
Dec 3, 2015
Accepted (ET)
Dec 7, 2015 · 10:54 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001327467
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 3, 2015 | P | 5,000 | $1.865 | A | 6,277 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This constitutes the weighted average purchase price. The prices range from $1.85 to $1.8693. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2These securities are owned by Scott D. Morenstein, who is the Reporting Person. The 1,123,612 shares of common stock previously reported on the Reporting Person's Form 4 are no longer being included because the Reporting Person does not have beneficial ownership of these securities.